Clinical development success rates for investigational drugs

Published on Jan 1, 2014in Nature Biotechnology
· DOI :10.1038/nbt.2786
Michael Hay1
Estimated H-index: 1
David W. Thomas2
Estimated H-index: 2
+ 2 AuthorsJesse Rosenthal1
Estimated H-index: 1
The most comprehensive survey of clinical success rates across the drug industry to date shows productivity may be even lower than previous estimates.
  • References (15)
  • Citations (867)
📖 Papers frequently viewed together
378 Citations
2,744 Citations
510 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Rebecca Henderson (MIT: Massachusetts Institute of Technology)H-Index: 34
#2Iain M. Cockburn (NBER: National Bureau of Economic Research)H-Index: 42
We examine the relationship between firm size and research productivity in the pharmaceutical industry. Using detailed internal firm data, we find that larger research efforts are more productive, not only because they enjoy economies of scale, but also because they realize economies of scope by sustaining diverse portfolios of research projects that capture internal and external knowledge spillovers. In pharmaceuticals, economies of scope in research are important in shaping the boundaries of t...
938 Citations
91 CitationsSource
#1Kenneth I. Kaitin (Tufts Center for the Study of Drug Development)H-Index: 24
#2Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
The first decade of the 21st century was a challenging period for the pharma sector and could prove to be a turning point in the evolution of the industry. We examine drug development performance metrics for new product approvals during 2000–2009 and compare them with those of the prior two decades. The results indicate that, whereas total approvals are currently at a 25-year low, the percentage of priority products is nearly 50% of the total—a 30-year high. Following enactment of the Prescripti...
234 CitationsSource
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
#2L Feldman (Tufts Center for the Study of Drug Development)H-Index: 3
Last. A Wilson (Tufts Center for the Study of Drug Development)H-Index: 1
view all 4 authors...
453 CitationsSource
#1Ashish Arora (NBER: National Bureau of Economic Research)H-Index: 45
#2Alfonso Gambardella (Bocconi University)H-Index: 41
Last. Nicola Carmine Salerno (IMT Institute for Advanced Studies Lucca)H-Index: 30
view all 4 authors...
This paper compares the innovation performance of established pharmaceutical firms and biotech companies, controlling for differences in the scale and scope of research. We develop a structural model to analyze more than 3,000 drug research and development projects advanced to preclinical and clinical trials in the United States between 1980 and 1994. Key to our approach is careful attention to the issue of selection. Firms choose which compounds to advance into clinical trials. This choice depe...
68 CitationsSource
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
#2Henry G Grabowski (Duke University)H-Index: 39
The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been published on the costs of developing the types of molecules on which biotech firms have focused. This study represents a first attempt to get a sense for the magnitude of the RDmAbsr). We utilize drug-specific data on cash outlays, development times, and success in obtaining regulatory marketing approval to e...
393 CitationsSource
#1Rosa M. Abrantes-Metz (NYU: New York University)H-Index: 7
#2Christopher Adams (Federal Trade Commission)H-Index: 9
Last. Albert D. Metz (Moody's Investors Service)H-Index: 3
view all 3 authors...
This paper estimates a duration model of late stage drug development in the pharmaceutical industry using publicly available data. The paper presents descriptive results on the estimated relationship between a particular drug's characteristics such as therapy category, route of administration and originator's size, and that drug's pathway through the three stages of human clinical trials and regulatory review. The results suggest that drugs with longer durations are less likely to succeed, drugs...
44 CitationsSource
#1Patricia M. Danzon (UPenn: University of Pennsylvania)H-Index: 37
#2Sean Nicholson (UPenn: University of Pennsylvania)H-Index: 29
Last. Nuno Pereira (UPenn: University of Pennsylvania)H-Index: 17
view all 3 authors...
Using data on over 900 firms for the period 1988–2000, we estimate the effect on phase-specific biotech and pharmaceutical RD L22; L23; L65; O32
179 CitationsSource
Critics decry the lack of 'truly innovative' new medicines and question the role of the pharmaceutical industry in creating the few that are developed. Is this an accurate portrayal of the state of pharmaceutical innovation? Does major pharma still innovate? If so, how? Must the industry innovate to survive? These and related issues are discussed.
83 CitationsSource
#1Ismail Kola (MSD: Merck & Co.)H-Index: 46
#2John Landis (Schering-Plough)H-Index: 1
2,744 CitationsSource
Cited By867
#1Jianlin Xu (BMS: Bristol-Myers Squibb)H-Index: 12
#2Matthew S. Rehmann (BMS: Bristol-Myers Squibb)H-Index: 2
Last. Zheng Jian Li (BMS: Bristol-Myers Squibb)H-Index: 19
view all 8 authors...
The goal of cell culture process intensification is to increase volumetric productivity, generally by increasing viable cell density (VCD), cell specific productivity or production bioreactor utilization in manufacturing. In our previous study, process intensification in fed-batch production with higher titer or shorter duration was demonstrated by increasing the inoculation seeding density (SD) from ~ 0.6 (Process A) to 3–6 × 106 cells/mL (Process B) in combination with media enrichment. In thi...
1 CitationsSource
#1A. Subramani (New College of Florida)
#2L. Benazir Ali (New College of Florida)
Last. T.K. Shabeer (New College of Florida)
view all 4 authors...
Abstract This research work was emphasized about two different new symmetrical diol monomers: (i) Schiff base monomers (1a-1d) and (ii) 4-Arylidine curcumin monomers (2a, 2b). Formulations of all monomers have been deduced by elemental analysis and spectral data (FT IR, 1H NMR, 13C NMR, and GC/MS spectroscopy). Investigations on photophysical properties of monomers have been studied in THF using steady state absorption, fluorescence, and excited-state time-resolved fluorescence techniques. The c...
#1Ayaz Anwar (Sunway University)H-Index: 10
#2Akshinee Soomaroo (Sunway University)
Last. Naveed Ahmed Khan (AUS: American University of Sharjah)H-Index: 35
view all 5 authors...
Abstract Acanthamoeba castellanii is an opportunistic protozoan responsible for serious human infections including Acanthamoeba keratitis and granulomatous amoebic encephalitis. Despite advances in antimicrobial therapy and supportive care, infections due to Acanthamoeba are main a major public concern. Current methods of treatment are not fully effective against both the trophozoite and cyst forms of A. castellanii and are often associated with severe adverse effects, host cell cytotoxicity and...
#1Jermaine D. Jones (Columbia University)H-Index: 18
#2Shanna Babalonis (UK: University of Kentucky)H-Index: 8
Last. Sandra D. Comer (Columbia University)H-Index: 40
view all 13 authors...
: Preclinical data indicate that selective kappa opioid receptor antagonists reduce nicotine self-administration and withdrawal symptoms. The aim of the current study was to determine whether treatment with CERC-501, an orally available, potent, and selective kappa opioid receptor antagonist, could alleviate nicotine withdrawal and craving and mitigate mood alterations associated with nicotine withdrawal in humans. Healthy, adult cigarette smokers were enrolled into this randomized, multisite, d...
1 CitationsSource
#1You Han Bae (UofU: University of Utah)H-Index: 77
#2Kinam Park (Purdue University)H-Index: 78
Abstract Drug delivery systems are developed to maximize drug efficacy and minimize side effects. As drug delivery technologies improve, the drug becomes safer and more comfortable for patients to use. During the last seven decades, extraordinary progress has been made in drug delivery technologies, such as systems for long-term delivery for months and years, localized delivery, and targeted delivery. The advances, however, will face a next phase considering the future technologies we need to ov...
#1Mateusz T. Wasylewski (Jagiellonian University Medical College)H-Index: 2
#2Karolina Strzebonska (Jagiellonian University Medical College)H-Index: 2
Last. Marcin Waligóra (Jagiellonian University Medical College)H-Index: 9
view all 6 authors...
Objectives Drug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrogates of social value of Phase 1 trials performed in pediatric oncology: rates of approval of tested interventions, transition to further phases of testing and citation in subsequent primary research reports. Methods We performed an analysis on a sub...
p-Values are viewed by many as the root cause of the so-called replication crisis, which is characterized by the prevalence of positive scientific findings that are contradicted in subsequent studi...
#1Joshua B. Holmes (Case Western Reserve University)H-Index: 1
#2Julian E. Stelzer (Case Western Reserve University)H-Index: 13
#1Palanisamy Prakash (Periyar University)H-Index: 1
#2Durairaj Vijayasarathi (CSIR: Council of Scientific and Industrial Research)
Last. Rengarajan Manivasagaperumal (Government Arts College, Coimbatore)
view all 5 authors...
Plants produced natural generating products play a significant role in drug discovery of new bioactive compounds and these are used for advancement of innovative curative drugs for specific target health diseases. In this study Docking and ADME/T virtual screening method are apply for in drug discovery and can be divided into ligand- and target structure-based. The aim of this study was to analyze the Decalepis hamiltonii isolated compounds by using the evaluation of molecular docking and virtua...
#1Ann Lin (Stanford University)
#2Jason M. Sheltzer (CSHL: Cold Spring Harbor Laboratory)H-Index: 13
Cancer ‘genetic dependencies’ — genes whose products are essential for cancer cell fitness — are promising targets for therapeutic development. However, recent evidence has cast doubt on the validity of several putative dependencies that are currently being targeted in cancer clinical trials, underscoring the challenges inherent in correctly identifying cancer-essential genes. Here we review several common techniques and platforms for discovering and characterizing cancer dependencies. We discus...